• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H 4 4 R‐antagonist ( JNJ JNJ ‐39758979) in adults with uncontrolled asthma
【24h】

Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H 4 4 R‐antagonist ( JNJ JNJ ‐39758979) in adults with uncontrolled asthma

机译：2A相，随机，双盲，安慰剂控制，多期，并行群体在具有不受控制的哮喘的成人中的H 4 4 R-拮抗剂（JNJ JNJ-39758979）的平行群体研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background The effects of H 4 R antagonists in preclinical asthma models support the study of antagonists of the H 4 R in the treatment of asthma in humans. JNJ ‐39758979 is a potent and highly selective oral H 4 R antagonist. Objective We sought to evaluate the safety and efficacy of the H 4 R‐antagonist JNJ ‐39758979 in adult patients with uncontrolled asthma. Methods One hundred and fifteen eligible patients were randomly assigned to JNJ ‐39758979 300?mg or placebo once daily for 12?weeks in this phase 2a, double‐blind, multicenter, placebo‐controlled study. Primary efficacy was assessed via week‐12 change from baseline in pre‐bronchodilator forced expiratory volume in 1?second ( FEV 1 ). Secondary efficacy assessments included patient‐reported outcome ( PRO ) asthma assessments (Asthma Daily Diary data [ AM and PM peak expiratory flow rate, number of puffs of albuterol/salbutamol, the presence of nocturnal awakenings and asthma symptom score]). Results The study did not meet the primary end‐point. However, nominally significant improvements in pre‐bronchodilator FEV 1 were observed with JNJ ‐39758979 versus placebo at week 12 in pre‐specified subgroups with elevated exhaled nitric oxide, sputum eosinophils or blood eosinophils at baseline. Nominally significant improvements across PRO assessments were consistently observed in the overall population, as well as in eosinophilic subgroups. Safety, such as adverse event rates, was comparable between JNJ ‐39758979 and placebo. No serious adverse events were reported. No clinically relevant changes in laboratory values were observed. Conclusions and Clinical Relevance The findings suggest potential benefit of H 4 R antagonists on lung function and asthma control in eosinophilic asthma patients and warrant further evaluation of this mechanism in asthma with eosinophilic inflammation. NCT 00946569.
机译：None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号